Why the study?
Many patients with hypercholesterolaemia fail to reach therapeutic goals, are statin intolerant, or remain at high risk of ischaemic events despite optimal statin therapy, motivating interest in PCSK9 inhibition as a lipid-lowering approach.
Answers are grounded in this paper and cite their sources.
Review evaluates PCSK9 inhibition via monoclonal antibodies for dyslipidaemia, highlighting therapeutic potential for high-risk patients who do not reach goals with statin therapy.
Statins are recommended as first-line therapy for patients with hypercholesterolaemia. A sizable proportion of patients, however, does not reach therapeutic goals, is statin intolerant, or, despite optimal statin therapy, is at high risk of ischaemic events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in lipid metabolism and several comorbidities. Monoclonal antibodies targeting PCSK9 are a new lipid-lowering approach with the potential to improve clinical outcomes in patients with dyslipidaemia. In this review, we discuss current experimental and clinical evidence of the role of PCSK9 and its inhibition on lipid metabolism and several pathologic conditions with a focus on clinical outcomes. A state-of-the-art analysis of current clinical evidence and future directions on PCSK9 and its inhibition is provided.
No takes yet. Share an insight, caveat, or question.
Navarese et al. (2015) conducted a review in Hypercholesterolaemia and dyslipidaemia. Monoclonal antibodies targeting PCSK9 was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: